Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Mar 4;31(3):1323-1334.
doi: 10.3390/curroncol31030100.

A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia

Lilit Harutyunyan  1   2 , Evelina Manvelyan  3 , Nune Karapetyan  1   4   5   6 , Samvel Bardakhchyan  4   5   6 , Aram Jilavyan  7   8 , Gevorg Tamamyan  5   6   9   10 , Armen Avagyan  1   2 , Liana Safaryan  4   6 , Davit Zohrabyan  4   6 , Narine Movsisyan  1   2   11   12 , Anna Avinyan  2 , Arevik Galoyan  2 , Mariam Sargsyan  2   5 , Martin Harutyunyan  4   6 , Hasmik Nersoyan  7   13 , Arevik Stepanyan  7   13 , Armenuhi Galstyan  7   14 , Samvel Danielyan  6 , Armen Muradyan  1 , Gagik Jilavyan  1   7   8
Affiliations
Multicenter Study

A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia

Lilit Harutyunyan et al. Curr Oncol. .

Abstract

Background: Annually, approximately 200 new ovarian cancer cases are diagnosed in Armenia, which is considered an upper-middle-income country. This study aimed to summarize the survival outcomes of patients with relapsed ovarian cancer in Armenia based on the type of recurrence, risk factors, and choice of systemic treatment.

Methods: This retrospective case-control study included 228 patients with relapsed ovarian cancer from three different institutions.

Results: The median age of the patients was 55. The median follow-up times from relapse and primary diagnosis were 21 and 48 months, respectively. The incidence of platinum-sensitive relapse was 81.6% (186), while platinum-resistant relapse was observed in only 18.4% (42) of patients. The median post-progression survival of the platinum-sensitive group compared to the platinum-resistant group was 54 vs. 25 months (p < 0.001), respectively, while the median survival after relapse was 25 vs. 13 months, respectively; three- and five-year post-progression survival rates in these groups were 31.2% vs. 23.8%, and 15.1% vs. 9.5%, respectively (p = 0.113).

Conclusions: Overall, despite new therapeutic approaches, ovarian cancer continues to be one of the deadly malignant diseases affecting women, especially in developing countries with a lack of resources, where chemotherapy remains the primary available systemic treatment for the majority of patients. Low survival rates demonstrate the urgent need for more research focused on this group of patients with poor outcomes.

Keywords: chemotherapy; platinum-refractory relapse; platinum-resistant relapse; platinum-sensitive relapse; recurrent ovarian cancer; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

L.H. reports lecture fees and travel support from Roche and Novartis Pharmaceuticals outside of the submitted work.

Figures

Figure 1
Figure 1
Age groups of patients with relapsed ovarian cancer.
Figure 2
Figure 2
Kaplan–Maier curves based on patients’ ages at the time of diagnosis in the platinum-sensitive group.
Figure 3
Figure 3
Survival functions based on the type of relapse (PPS).
Figure 4
Figure 4
PFS in the platinum-sensitive group.
Figure 5
Figure 5
Proportions of three-year and five-year PPS in the (a) platinum-sensitive and (b) platinum-resistant groups.
See this image and copyright information in PMC

References

    1. Cabasag C.J., Fagan P.J., Ferlay J., Vignat J., Laversanne M., Liu L., van der Aa M.A., Bray F., Soerjomataram I. Ovarian Cancer Today and Tomorrow: A Global Assessment by World Region and Human Development Index Using GLOBOCAN 2020. Int. J. Cancer. 2022;151:1535–1541. doi: 10.1002/ijc.34002. - DOI - PubMed
    1. Ovarian Cancer By The Numbers|OCRA. [(accessed on 10 February 2024)]. Available online: https://ocrahope.org/get-the-facts/statistics/
    1. Ovarian Cancer Statistics|How Common is Ovarian Cancer|American Cancer Society. [(accessed on 10 February 2024)]. Available online: https://www.cancer.org/cancer/types/ovarian-cancer/about/key-statistics.....
    1. Statistical Committee of the Republic of Armenia Statistical Yearbook of Armenia 2023: Health and Healthcare. [(accessed on 10 February 2024)]. Available online: https://nih.am/assets/pdf/atvk/2d5537b6227666a32f97571d7dd15420.pdf.
    1. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 1.2024. [(accessed on 10 February 2024)]. Available online: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.

Publication types